Australia markets closed

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.67000.0000 (0.00%)
As of 03:19PM EDT. Market open.
Full screen
Loading interactive chart…
  • Zacks

    Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track

    Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.

  • GlobeNewswire

    Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

    IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in MayMr. Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D. appointed as Directors of Cellectis’ Board of DirectorsCash position1 of $135 million as of June 30, 2022 Conference call scheduled for 8AM ET/2PM CET on August 5, 2022 NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) --

  • GlobeNewswire

    Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

    UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01 expected to begin in second half of the year NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and